RE:RE:RE:RE:RE:RE:RE:RE:RE:Not surprisingThe other way to look at it is, this was an opportunity to share the tree so a friendly party can start to accumulate
scarlet1967 wrote: Paul last CC:
"Okay. Well, as you know, we have a basket trial now composed of 70 patients. We have targeted very specific tumors for which we know the, SORT1 expression is high. Now, we have a Fast Track designation, which allows us to have ongoing discussion with the FDA. So, we could modify this basket trial along the way we can. There are companies that are modifying their Phase 1b trials in many, many different ways..."
Today many bailed out due to their interpretation of yesterday's short PR.
In my opinion they could have mitigated the damage by organizing the CC this morning clarifying why in their opinion they still are willing to allocate resources to the project? Again many shareholders are, were and will be investing in the company for their oncology programs, ignoring the need for some more detailed explanation for their plans is ignoring all those shareholders which costed more than 30 percent of company's valuation. To me this was absolutely not the right way to communicate with a large group of your investors.